您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
Brief News on Innovation
Professor Song Guangyuan and His Team at Beijing Anzhen Hospital have Successfully  Completed the First Day Enrollment in the Multi-Center Registration Clinical Trial of  TaurusTrio™
2023.07.31
Professor Song Guangyuan and His Team at···
On July 26, 2023, Professor Song Guangyuan, the Director of the Heart Valve Intervention Center at B···
NMPA APPROVAL FOR REGISTRATION APPLICATION OF DCwire™ MICRO GUIDEWIRE
2023.07.07
NMPA APPROVAL FOR REGISTRATION APPLICATI···
This announcement is made by Peijia Medical Limited (the “Company”, together with its subsidiaries,···
First Asian Commercial Implants with the Trilogy Heart Valve System performed by Dr. Michael Lee and His Team in Queen Elizabeth Hospital in Hong Kong
2023.05.18
First Asian Commercial Implants with the···
On May 12th, 2023, Dr. Michael Lee and his team from the Cardiology Department of Queen Elizabeth Ho···
FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER REGISTRATION CLINICAL TRIAL OF GeminiOne® TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEM IN CHINA
2022.12.04
FIRST PATIENT ENROLLMENT IN THE MULTI-CE···
FIRST PATIENT ENROLLMENT IN THE MULTI-CENTER REGISTRATION CLINICAL TRIAL OF GeminiOne® TRANSCATHET···
FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL TRIAL OF THE MonarQ TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM IN THE WORLD
2022.11.25
FIRST PATIENT IMPLANT IN THE FIRST-IN-MA···
FIRST PATIENT IMPLANT IN THE FIRST-IN-MAN CLINICAL TRIAL OF THE MonarQ TRANSCATHETER TRICUSPID VALV···
FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION CLINICAL TRIAL OF PEIJIA HighLife® TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM IN CHINA
2022.11.14
FIRST PATIENT IMPLANT IN MULTI-CENTER RE···
FIRST PATIENT IMPLANT IN MULTI-CENTER REGISTRATION CLINICAL TRIAL OF PEIJIA HighLife® TRANSCATHETER···
Peijia Medical Fluxcap® Balloon Guide Catheter Obtained NMPA Approval
2022.06.09
Peijia Medical Fluxcap® Balloon Guide Ca···
On June 8, 2022, Peijia Medical received the approval from the National Medical Products Administrat···
Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter Obtained NMPA Approval
2022.05.24
Peijia Medical Tethys AS® Aspiration Cat···
Peijia Medical Tethys AS® Aspiration Catheter and Fastunnel® Delivery Balloon Dilation Catheter Obta···
NMPA Approval for Registration Application of Syphonet®️ Stent Retriever
2022.02.17
NMPA Approval for Registration Applicati···
On February 11, 2022, Peijia Medical Limited (the “Company”) received the approval from the National···
The First Clinical Case using HighLife Transseptal Mitral Valve Replacement Technology was successfully carried out in Asia
2022.01.08
The First Clinical Case using HighLife T···
On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement (“···
Peijia Medical Announces First Patient Treatment in the Clinical Trial of its Innovative Non-implant
2021.11.01
Peijia Medical Announces First Patient T···
A major breakthrough in interventional therapy for heart valve disease and an innovative progress in···
Peijia Medical Announces First Patient Implant in the Clinical Trial of its Third-Generation Transca
2021.09.14
Peijia Medical Announces First Patient I···
Peijia Medical today announced the initiation of its multi-center clinical trial for TaurusNXT®, the···
Top